Key result
Melatonin attenuates doxorubicin-induced cardiotoxicity and LV dysfunction in preclinical models, though clinical data remain limited.
Why the study?
Clinical application of doxorubicin is limited by cardiotoxicity, and clinical evidence regarding the impact of melatonin in reducing this cardiotoxicity is still limited.
Does melatonin prevent or attenuate doxorubicin-induced cardiotoxicity without interfering with chemotherapy efficacy?
Does melatonin prevent or attenuate doxorubicin-induced cardiotoxicity without interfering with chemotherapy efficacy?
Preclinical evidence strongly supports melatonin's cardioprotective effects against doxorubicin-induced cardiotoxicity via antioxidative, mitochondrial-protective, and anti-cell death mechanisms without compromising antitumor efficacy, warranting validation in high-quality clinical trials.
Answers are grounded in this paper and cite their sources.
Does not yet support melatonin with doxorubicin; leaves open its clinical efficacy and safety for randomized trials.
Doxorubicin is a potent chemotherapeutic drug; however, its clinical application has been limited due to its cardiotoxicity. One of the major mechanisms of doxorubicin-induced cardiotoxicity is the induction of oxidative stress. Evidence from in vitro and in vivo studies demonstrates that melatonin attenuated the increase in ROS production and lipid peroxidation from doxorubicin. Melatonin has been shown to exert protective effects on mitochondria damaged by doxorubicin via attenuating the depolarization of the mitochondrial membrane, restoring ATP production, and maintaining mitochondrial biogenesis. Doxorubicin increased mitochondrial fragmentation which impaired mitochondrial function; however, these adverse effects were reversed by melatonin. Melatonin also modulated cell death pathways by suppressing apoptotic and ferroptotic cell death caused by doxorubicin. These beneficial effects of melatonin could be responsible for the attenuation of changes in ECG, left ventricular dysfunction, and hemodynamic deterioration caused by doxorubicin. Despite these potential benefits, clinical evidence regarding the impact of melatonin in reducing cardiotoxicity induced by doxorubicin is still limited. Further clinical studies are justified to evaluate the efficacy of melatonin in protecting against doxorubicin-induced cardiotoxicity. This valuable information can be used to warrant the use of melatonin in a clinical setting under this condition.
No takes yet. Share an insight, caveat, or question.
Attachaipanich et al. (2023) conducted a review in Doxorubicin-induced cardiotoxicity. Melatonin vs. Doxorubicin without melatonin or control was evaluated on Doxorubicin-induced cardiotoxicity (oxidative stress, mitochondrial dysfunction, cell death, ECG changes, and LV dysfunction). Melatonin attenuated doxorubicin-induced oxidative stress, mitochondrial damage, apoptosis, ferroptosis, ECG changes, and LV dysfunction in preclinical studies, though clinical evidence remains limited.
Synapse has enriched 10 related papers. Consider them for comparative context: